Precision oncology represents an exciting shift in cancer treatment from a one-size-fits-all approach to personalized care based on each patient's unique cancer and molecular makeup. In this episode, we'll explore how precision oncology is transforming the landscape of cancer care and improving outcomes at leading hospitals like St. Jude Children’s Research Hospital. We'll discuss the latest precision diagnostic technologies enabling doctors to analyze a tumor's molecular profile and match targeted therapies to save lives. Join us as we investigate the promise of precision medicine to make cancer treatment more effective and more equitable. Guests include: Rick Shadyac, President and CEO at ALSAC, the fundraising and awareness organization for St. Jude Children’s Research Hospital, a Cambridge Associates client Matt Gevaert, Co-Founder and Board Member at Kiyatec Jason Robart, Co-Founder & Managing Partner at Seae Ventures Jeff Blazek, Partner and Head of the Northeast & Midwest Endowment & Foundation Practice at Cambridge Associates, who works with ALSAC/St. Jude as one of his clients, in partnership with Anurag Pandit, CIO of ALSAC/SJCRH, and the Investment Department. Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related